The tumor lysis syndrome.
作者信息
Howard Scott C, Jones Deborah P, Pui Ching-Hon
机构信息
Department of Oncology and International Outreach Program, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
出版信息
N Engl J Med. 2011 May 12;364(19):1844-54. doi: 10.1056/NEJMra0904569.
Abstract
摘要
相似文献
1
The tumor lysis syndrome.
N Engl J Med. 2011 May 12;364(19):1844-54. doi: 10.1056/NEJMra0904569.
2
Tumor lysis syndrome and acute renal failure--an increasing spectrum of presentations.
Clin Nephrol. 2007 Sep;68(3):186-9. doi: 10.5414/cnp68186.
3
Tumor lysis syndrome: pathogenesis and management.
Pediatr Nephrol. 1995 Apr;9(2):206-12. doi: 10.1007/BF00860751.
4
Tumour lysis syndrome.
Med Clin (Barc). 2019 May 17;152(10):397-404. doi: 10.1016/j.medcli.2018.10.029. Epub 2019 Jan 3.
5
Managing tumor lysis syndrome in 2010.
Leuk Lymphoma. 2010 Feb;51(2):179-80. doi: 10.3109/10428190903488788.
6
Rasburicase for Tumor Lysis Syndrome.
Am J Ther. 2019 Jan/Feb;26(1):e118-e121. doi: 10.1097/MJT.0000000000000462.
7
[Tumor lysis syndrome].
Nihon Rinsho. 2012 Aug;70 Suppl 6:423-7.
8
Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.
Am J Kidney Dis. 2010 May;55(5 Suppl 3):S1-13; quiz S14-9. doi: 10.1053/j.ajkd.2009.10.056.
9
[Acute renal failure in patients with tumor lysis syndrome].
Nihon Rinsho. 2004 May;62 Suppl 5:486-90.
10
[Acute kidney injury secondary to steroid-induced tumor lysis in an adolescent with acute lymphoblastic leukemia: role of urinary alkalinisation and peritoneal dialysis].
Arch Argent Pediatr. 2012 Dec;110(6):e118-22. doi: 10.5546/aap.2012.e118.
引用本文的文献
1
Characterizing the Real-World Risks of Kidney Injuries Associated with Chimeric Antigen Receptor T Cell Therapies-Evidence and Safety.
Health Data Sci. 2025 Sep 2;5:0325. doi: 10.34133/hds.0325. eCollection 2025.
2
Long-term outcomes of venetoclax and ibrutinib in Japanese patients with relapsed/refractory mantle cell lymphoma.
Int J Clin Oncol. 2025 Sep 2. doi: 10.1007/s10147-025-02865-4.
3
Real-World Safety and Efficacy of Venetoclax in Chronic Lymphocytic Leukemia: A Single-Center Comparative Analysis With Randomized Clinical Trials.
Adv Hematol. 2025 Aug 19;2025:3910332. doi: 10.1155/ah/3910332. eCollection 2025.
4
Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report.
Reports (MDPI). 2024 Nov 29;7(4):108. doi: 10.3390/reports7040108.
5
Management of acute kidney injury in tumor lysis syndrome: a narrative review.
Intern Emerg Med. 2025 Jul 19. doi: 10.1007/s11739-025-04050-x.
6
A Case of Spontaneous Tumor Lysis Syndrome With Acute Kidney Injury and the Timing of Chemotherapy.
Cureus. 2025 Jun 4;17(6):e85342. doi: 10.7759/cureus.85342. eCollection 2025 Jun.
7
Taurine alleviates hyperuricemia-induced nephropathy in rats: insights from microbiome and metabolomics.
Front Nutr. 2025 Jun 18;12:1587198. doi: 10.3389/fnut.2025.1587198. eCollection 2025.
8
Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications.
Ann Hematol. 2025 Jul;104(7):3537-3551. doi: 10.1007/s00277-025-06482-z. Epub 2025 Jul 1.
9
Nephrotoxicity of CAR-T therapy in patients with relapsed and refractory multiple myeloma.
Int Urol Nephrol. 2025 May 1. doi: 10.1007/s11255-025-04503-4.
10
Incidence of Tumour Lysis Syndrome in Patients with Acute Myeloid Leukemia During Initiation of Therapy with Azacitidine and Venetoclax: A Retrospective Chart Review from a Canadian Single-Centre Perspective.
Curr Oncol. 2025 Apr 2;32(4):213. doi: 10.3390/curroncol32040213.
本文引用的文献
1
Genetic disorders of renal phosphate transport.
N Engl J Med. 2010 Jun 24;362(25):2399-409. doi: 10.1056/NEJMra0904186.
2
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
Intern Med. 2010;49(11):991-4. doi: 10.2169/internalmedicine.49.3153. Epub 2010 Jun 1.
3
Tumor lysis syndrome and acute kidney injury: evaluation, prevention, and management.
Am J Kidney Dis. 2010 May;55(5 Suppl 3):S1-13; quiz S14-9. doi: 10.1053/j.ajkd.2009.10.056.
4
A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults.
Eur J Haematol. 2010 Aug;85(2):177-9. doi: 10.1111/j.1600-0609.2010.01457.x. Epub 2010 Apr 12.
5
Oral phosphate binders in patients with kidney failure.
N Engl J Med. 2010 Apr 8;362(14):1312-24. doi: 10.1056/NEJMra0912522.
6
Tumor lysis syndrome associated with carboplatin and paclitaxel in a woman with recurrent endometrial cancer.
Int J Gynaecol Obstet. 2010 Jun;109(3):254. doi: 10.1016/j.ijgo.2010.02.005. Epub 2010 Apr 1.
7
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
J Oncol Pharm Pract. 2011 Sep;17(3):147-54. doi: 10.1177/1078155210364180. Epub 2010 Mar 23.
8
Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus.
Br J Haematol. 2010 May;149(4):578-86. doi: 10.1111/j.1365-2141.2010.08143.x. Epub 2010 Mar 16.
9
Managing tumor lysis syndrome in 2010.
Leuk Lymphoma. 2010 Feb;51(2):179-80. doi: 10.3109/10428190903488788.
10
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
World J Gastroenterol. 2009 Sep 21;15(35):4464-6. doi: 10.3748/wjg.15.4464.
Zotero 插件